Clinical Trial

Continous Positive Airway Pressure (CPAP) Support for Acute Hypoxemic Respiratory Failure in Burkina Faso

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 28, 2025 (before its estimated January 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
Acute respiratory failure (ARF) is a frequent medical emergency, involving high costs for health organizations and patients who often require intensive care and respiratory assistance. According to an international study, 61% of hypoxemic patients in intensive care receive invasive ventilation \[3\]. Invasive mechanical ventilation is often unavailable in low-income countries and non-invasive ventilatory supports such as continuous positive airway pressure (CPAP) and high-flow oxygen therapy (HFO) were very useful during the COVID-19 pandemic. They reduced the rate of intubation and ICU admissions. In addition, CPAP can be used without a ventilator, no electricity is required. So, it could be a support of choice in low-income countries. Used of Boussignac-type CPAP could potentially reduce the recourse to intubation in patients with acute hypoxemic respiratory failure in a context where access to invasive ventilation remains very limited.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-30.
Status change: Not Yet Recruiting → Recruiting 2025-07-23
Trial Details
NCT Number NCT06912360
Lead Sponsor Université NAZI BONI
Collaborators: Assistance Publique - Hôpitaux de Paris
Conditions Acute Respiratory Failure
Enrollment 240 participants
Start Date 2025-07-09
Primary Completion 2026-01-20 (estimated)
Study Completion 2026-02-20 (estimated)
Updated on ClinicalTrials.gov 2025-07-28